[go: up one dir, main page]

MX2018014868A - Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma. - Google Patents

Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.

Info

Publication number
MX2018014868A
MX2018014868A MX2018014868A MX2018014868A MX2018014868A MX 2018014868 A MX2018014868 A MX 2018014868A MX 2018014868 A MX2018014868 A MX 2018014868A MX 2018014868 A MX2018014868 A MX 2018014868A MX 2018014868 A MX2018014868 A MX 2018014868A
Authority
MX
Mexico
Prior art keywords
nintedanib
compositions
methods
glaucoma surgery
improving
Prior art date
Application number
MX2018014868A
Other languages
English (en)
Inventor
Yang Rong
Ni Jinsong
Original Assignee
Cloudbreak Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018014868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cloudbreak Therapeutics Llc filed Critical Cloudbreak Therapeutics Llc
Publication of MX2018014868A publication Critical patent/MX2018014868A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan en el presente documento composiciones y métodos de uso de nintedanib para mejorar la tasa de éxito de la cirugía de filtración del glaucoma. Puede usarse nintedanib solo o en combinación con un fármaco antimetabolito en una formulación ocular tópica o de implante.
MX2018014868A 2016-06-02 2017-05-26 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma. MX2018014868A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344870P 2016-06-02 2016-06-02
US201662344878P 2016-06-02 2016-06-02
PCT/US2017/034792 WO2017210130A1 (en) 2016-06-02 2017-05-26 Compositions and methods of using nintedanib for improving glaucoma surgery success

Publications (1)

Publication Number Publication Date
MX2018014868A true MX2018014868A (es) 2019-09-13

Family

ID=60477780

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2018014868A MX2018014868A (es) 2016-06-02 2017-05-26 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2018014869A MX389460B (es) 2016-06-02 2017-05-26 Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
MX2024007658A MX2024007658A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2022000754A MX2022000754A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2018014869A MX389460B (es) 2016-06-02 2017-05-26 Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
MX2024007658A MX2024007658A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
MX2022000754A MX2022000754A (es) 2016-06-02 2018-11-30 Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal.

Country Status (10)

Country Link
US (5) US11246864B2 (es)
EP (3) EP3463315B1 (es)
JP (4) JP7079243B2 (es)
KR (6) KR102408596B1 (es)
CN (3) CN109561985B (es)
AU (6) AU2017274195B2 (es)
BR (2) BR112018074454A2 (es)
CA (2) CA3025325A1 (es)
MX (4) MX2018014868A (es)
WO (2) WO2017210132A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3302379B1 (en) 2015-06-06 2023-11-22 Cloudbreak Therapeutics, LLC Compositions and methods for treating pterygium
KR102408596B1 (ko) 2016-06-02 2022-06-13 에이디에스 테라퓨틱스 엘엘씨 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
US20190388407A1 (en) 2017-02-12 2019-12-26 Aiviva Biopharma, Inc. Multikinase inhibitors of vegf and tfg beta and uses thereof
GB201714392D0 (en) 2017-09-07 2017-10-25 Marsteller Laurence Methods and devices for treating glaucoma
WO2021142298A1 (en) * 2020-01-08 2021-07-15 Radiance Therapeutics, Inc. Methods, systems, and compositions for maintaining functioning drainage blebs
AU2019272871B2 (en) * 2018-05-25 2025-02-27 Ads Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
KR20240139087A (ko) * 2018-08-15 2024-09-20 아이비바 바이오파마, 인크. Vegf 및 tgf 베타의 다중 키나아제 억제제 및 이의 용도
JP7489965B2 (ja) * 2018-08-28 2024-05-24 クラウドブレイク セラピューティクス リミテッド ライアビリティ カンパニー マルチキナーゼ阻害剤のエマルジョン製剤
US11197821B2 (en) * 2018-09-25 2021-12-14 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
CN112770703A (zh) 2018-09-28 2021-05-07 光辉疗法公司 用于维持与微创微巩膜造口术相关的功能性引流泡的方法、系统和组合物
WO2020113091A1 (en) 2018-11-29 2020-06-04 Marsteller Laurence J Ophthalmic brachytherapy systems and devices for application of beta radiation
KR20220061147A (ko) * 2019-09-10 2022-05-12 클라우드브레이크 테라퓨틱스, 엘엘씨 눈 외양에 대한 익상편-관련 걱정을 경감하기 위한 방법
CN110787127A (zh) * 2019-12-11 2020-02-14 龚雁 眼用温敏凝胶及其制备方法
AU2021244485B2 (en) 2020-03-25 2024-05-16 Ocular Therapeutix, Inc. Ocular implant containing a tyrosine kinase inhibitor
US20230263907A1 (en) * 2020-06-30 2023-08-24 Oculis SA Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
KR102769064B1 (ko) * 2020-12-30 2025-02-19 한국과학기술연구원 닌테다닙을 포함하는 암 치료 효과 증진용 조성물 및 이의 용도
USD1076086S1 (en) 2021-11-23 2025-05-20 Radiance Therapeutics, Inc. Opthalmic brachytherapy device
USD1076085S1 (en) 2021-11-23 2025-05-20 Radiance Therapeutics, Inc. Opthalmic brachytherapy device
CN116251186B (zh) * 2021-12-09 2025-04-25 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途
KR20260002666A (ko) 2023-04-11 2026-01-06 오큘라 테라퓨틱스, 인코포레이티드 악시티닙 다형체 iv를 포함하는 안구 임플란트
MX2023009955A (es) * 2023-08-24 2025-03-07 Sophia Holdings S A De C V Composiciones farmaceuticas oftalmicas que contienen dorzolamida, metodos para su preparacion y uso de las mismas.

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE240098T1 (de) 1997-02-14 2003-05-15 Kissei Pharmaceutical Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20060052286A1 (en) 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
US9993558B2 (en) * 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
US20080003219A1 (en) 2005-09-26 2008-01-03 Minu, L.L.C. Delivery of an ocular agent
WO2007038453A2 (en) 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US8558002B2 (en) 2006-11-16 2013-10-15 Allergan, Inc. Sulfoximines as kinase inhibitors
EP2134702B2 (en) 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
RU2351298C1 (ru) 2007-11-27 2009-04-10 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ профилактики рецидива птеригиума
UA107560C2 (uk) 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
PE20100254A1 (es) 2008-06-06 2010-04-21 Boehringer Ingelheim Int Forma de dosificacion farmaceutica en capsula que comprende una formulacion en suspension de un derivado de indolinona
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100185564A1 (en) 2009-01-21 2010-07-22 Mccormick & Company, Inc. Method and questionnaire for measuring consumer emotions associated with products
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
TW201201808A (en) 2010-01-06 2012-01-16 Glaxo Wellcome Mfg Pte Ltd Treatment method
JP5809169B2 (ja) 2010-01-22 2015-11-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 治療薬持続放出型腔内インプラント
CA2812744A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
CN102018686B (zh) 2010-12-16 2012-12-05 浙江大学医学院附属邵逸夫医院 含有丝裂霉素的膜剂及其制备方法
AU2012206527A1 (en) * 2011-01-13 2013-08-01 Novartis Ag BACE-2 inhibitors for the treatment of metabolic disorders
DK2714735T3 (da) 2011-06-03 2021-10-18 Xoma Technology Ltd Antistoffer, der er specifikke for TGF-beta
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
US20140296301A1 (en) 2011-06-28 2014-10-02 Bayer Pharma Aktiengesellschaft Topical ophthalmological pharmaceutical composition containing regoragenib
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
ES2946549T3 (es) 2012-01-13 2023-07-20 Xspray Pharma Ab Publ Composición farmacéutica de nilotinib
CN103212075B (zh) * 2012-01-19 2017-06-27 成都康弘生物科技有限公司 一种含有vegf拮抗剂的滴眼液
US20150037422A1 (en) 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
HK1208382A1 (en) 2012-05-03 2016-03-04 卡拉制药公司 Pharmaceutical nanoparticles showing improved mucosal transport
CN104379129A (zh) 2012-06-25 2015-02-25 拜尔健康护理有限责任公司 含有帕唑帕尼的局部眼科药物组合物
EP2863888A1 (en) 2012-06-25 2015-04-29 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing axitinib
US20150165028A1 (en) 2012-06-25 2015-06-18 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing cediranib
JP2017512748A (ja) 2012-06-25 2017-05-25 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ スニチニブを含んでいる眼科用局所医薬組成物
WO2014059233A1 (en) * 2012-10-11 2014-04-17 The Regents Of The University Of Colorado, A Body Corporate Ocular filtration devices, systems and methods
CN110893188A (zh) 2012-11-08 2020-03-20 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
CN104955471A (zh) 2012-11-15 2015-09-30 塔夫斯大学 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒
US8747852B1 (en) 2012-12-28 2014-06-10 Randal Tanh Hoang Pham Methods of treating pterygium
WO2014158863A1 (en) 2013-03-14 2014-10-02 Massachusetts Eye And Ear Infirmary Conjunctival diseases
DK2981248T3 (da) 2013-04-01 2020-11-30 Allergan Inc Mikrosfærelægemiddelleveringssystem til langvarig intraokulær frigivelse
CN116327482A (zh) 2013-05-03 2023-06-27 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
US20140378401A1 (en) 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
KR20160126983A (ko) 2014-01-16 2016-11-02 온토제네시스, 엘엘씨 안내 혈관신생 및/또는 누출 치료용 조성물 및 방법
CN114010788A (zh) * 2014-08-22 2022-02-08 奥克兰联合服务有限公司 通道调节剂
CN104448300B (zh) 2014-12-09 2017-01-11 西安医学院 低分子量l-聚谷氨酸-丝裂霉素c及其合成方法和应用
US10350211B2 (en) 2015-01-26 2019-07-16 University Of Washington Bumped kinase inhibitor compositions and methods for treating cancer
EP3302379B1 (en) 2015-06-06 2023-11-22 Cloudbreak Therapeutics, LLC Compositions and methods for treating pterygium
EP3692991A1 (de) 2015-06-09 2020-08-12 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
TWI700085B (zh) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 酪胺酸激酶抑制劑之眼用調配物的用途
JP2018525078A (ja) 2015-07-22 2018-09-06 インセプト・リミテッド・ライアビリティ・カンパニーＩｎｃｅｐｔ，Ｌｌｃ 被覆された涙点プラグ
CN108295072A (zh) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 尼达尼布防治眼部疾病的用途
CN106902117A (zh) * 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 一种预防或治疗脉络膜新生血管形成的药物
WO2017120600A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
JP7081818B2 (ja) 2016-02-04 2022-06-07 エーディーエス・セラピューティクス・エルエルシー 疾患治療のための抗体－薬剤相乗作用技術
KR102408596B1 (ko) 2016-06-02 2022-06-13 에이디에스 테라퓨틱스 엘엘씨 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법
US11278546B2 (en) 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
WO2018054077A1 (en) 2016-09-26 2018-03-29 Reyoung (Suzhou) Biology Science & Technology Co., Ltd Composition for treating ocular diseases and methods of usage and making
JP7030345B2 (ja) 2016-09-28 2022-03-07 メディコン ファーマシューティカルズ，インコーポレイテッド 眼の状態を処置する組成物および方法
CN116063221A (zh) 2017-03-14 2023-05-05 新源生物科技股份有限公司 尼达尼布的晶型
AU2019272871B2 (en) 2018-05-25 2025-02-27 Ads Therapeutics Llc A composition for treating ocular hyperemia and a method for treating ocular hyperemia with the same
CN110664757B (zh) 2018-11-19 2022-08-02 成都瑞沐生物医药科技有限公司 纳米晶滴眼剂、其制备方法及其应用
KR20220061147A (ko) 2019-09-10 2022-05-12 클라우드브레이크 테라퓨틱스, 엘엘씨 눈 외양에 대한 익상편-관련 걱정을 경감하기 위한 방법
CN115697333A (zh) 2020-02-19 2023-02-03 科尼尔赛德生物医学公司 包含阿西替尼的组合物和治疗眼部疾病的方法
CN116251186B (zh) 2021-12-09 2025-04-25 成都瑞沐生物医药科技有限公司 一种酪氨酸激酶抑制剂眼用制剂及其制备方法和用途

Also Published As

Publication number Publication date
MX2018014869A (es) 2019-09-13
KR20240049636A (ko) 2024-04-16
US11911379B2 (en) 2024-02-27
AU2017274195B2 (en) 2022-04-07
US20220125783A1 (en) 2022-04-28
AU2025200273A1 (en) 2025-01-30
JP2019518790A (ja) 2019-07-04
JP7475395B2 (ja) 2024-04-26
US11246864B2 (en) 2022-02-15
BR112018074450A2 (pt) 2019-03-19
EP3463315A1 (en) 2019-04-10
WO2017210130A1 (en) 2017-12-07
EP4248971A2 (en) 2023-09-27
US20200323844A1 (en) 2020-10-15
US20190290643A1 (en) 2019-09-26
JP7079243B2 (ja) 2022-06-01
AU2022202629A1 (en) 2022-05-19
KR20190040935A (ko) 2019-04-19
EP3463315A4 (en) 2020-01-15
KR102496234B1 (ko) 2023-02-06
CN109561985B (zh) 2022-03-04
JP7082115B2 (ja) 2022-06-07
KR102408596B1 (ko) 2022-06-13
CN109475506A (zh) 2019-03-15
US12491183B2 (en) 2025-12-09
CA3025325A1 (en) 2017-12-07
KR20190032300A (ko) 2019-03-27
CA3026118A1 (en) 2017-12-07
MX2022000754A (es) 2022-02-14
MX389460B (es) 2025-03-20
AU2024219639A1 (en) 2024-10-03
JP2022116191A (ja) 2022-08-09
EP4248971A3 (en) 2024-02-14
CN109561985A (zh) 2019-04-02
US20190015409A1 (en) 2019-01-17
AU2017274197B2 (en) 2022-02-10
EP3463315B1 (en) 2023-06-14
EP3463225A4 (en) 2020-03-11
US20240238279A1 (en) 2024-07-18
AU2022204216B2 (en) 2024-10-17
AU2022204216A1 (en) 2022-07-14
KR20220080222A (ko) 2022-06-14
JP2024083587A (ja) 2024-06-21
KR102657707B1 (ko) 2024-04-15
AU2022202629B2 (en) 2024-06-13
AU2017274197A1 (en) 2018-12-06
KR20230023812A (ko) 2023-02-17
EP3463315C0 (en) 2023-06-14
JP2019517578A (ja) 2019-06-24
EP3463225A1 (en) 2019-04-10
WO2017210132A1 (en) 2017-12-07
MX2024007658A (es) 2024-07-04
CN119656170A (zh) 2025-03-21
AU2017274195A1 (en) 2018-12-13
US10335408B2 (en) 2019-07-02
BR112018074454A2 (pt) 2019-03-19
US10688092B2 (en) 2020-06-23
KR20240052865A (ko) 2024-04-23

Similar Documents

Publication Publication Date Title
MX2024007658A (es) Composiciones y metodos de uso de nintedanib para mejorar el exito de la cirugia del glaucoma.
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
MX2019003364A (es) Composiciones oftalmicas que comprenden ciclosporina.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
EP3188688A4 (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
EP3153170A4 (en) Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
EP3137116A4 (en) Dendrimer compositions and their use in treatment of diseases of the eye
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
WO2016025666A8 (en) Tissue matrices and methods of treatment
EP4324454A3 (en) Cross-linking agents and associated methods
EP3651747A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISORDERS
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
WO2016001905A3 (en) Stable liquid ready-to-use injectable formulation of bortezomib
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EP3193867A4 (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye
MX2015000884A (es) Composicion odontologica de papaina en gel para el tratamiento atraumatico de caries y metodo para prepararla.
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2014117010A3 (en) Composition for ophthalmic administration
TW201613596A (en) Ophthalmic suspension preparation
IN2014MU00284A (es)
EP4335508A3 (en) (+)-azasetron for use in the treatment of ear disorders